You are here

Article Text

Article menu
Download PDFPDF
Letter
Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab
  1. C M G Cheung1,
  2. P I Murray1,
  3. C O S Savage2
  1. 1Ophthalmology, Division of Immunity and Infection, University of Birmingham, Birmingham, UK
  2. 2Nephrology, Division of Immunity and Infection, University of Birmingham, Birmingham, UK
  1. Correspondence to: Professor P I Murray Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, City Hospital, Dudley Road, Birmingham B18 7QU, UK; p.i.murraybham.ac.uk

https://doi.org/10.1136/bjo.2005.075689

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rituximab (Rituxan, Genentech, Inc, South San Francisco, CA, USA) is a new anti-CD20 B cell monoclonal antibody that has been used successfully to treat refractory cases of Wegener’s granulomatosis (WG).1–3 There has been no published report of its effect in Wegener’s associated eye disease. We describe the successful treatment of Wegener’s associated scleritis with rituximab.

    Case report

    A 21 year old man with WG, proved on renal biopsy and by anti-neutrophil cytoplasm antibody (ANCA) positivity 6 years earlier, presented with bilateral, painful, red eyes. On examination his visual acuities were 6/4 right eye and 6/5 left eye. Anterior segment examination showed subconjunctival haemorrhage, congested scleral vessels, scleral oedema, peripheral corneal infiltrates, and mild anterior …

    View Full Text